7.82
price down icon1.51%   -0.12
after-market After Hours: 7.82
loading
Amneal Pharmaceuticals Inc stock is traded at $7.82, with a volume of 3.30M. It is down -1.51% in the last 24 hours and up +5.39% over the past month. Amneal Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, markets, and distributes generic pharmaceutical products for various dosage forms and therapeutic areas. It operates through Generic and Specialty Pharma divisions. The company's generics portfolio includes approximately 200 product families marketed in various dosage forms, such as solid oral doses comprising tablets, capsules, and powders; liquids; sterile injectables; nasal sprays; inhalation and respiratory products; ophthalmics; films; transdermal patches; and topicals, as well as soft gel, complex molecule, and drug-device combinations. It is also involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders and parasitic infections; and biosimilar products. In addition, the company offers licensed and owned, niche, and mature branded products, as well as a pipeline of 505(b)(2) products for various therapeutic areas that primarily includes Unithroid for endocrinologists and primary care physicians through a contracted salesforce. Amneal Pharmaceuticals, Inc. has a partnership agreement with MabXience S.L. for the development of Avastin, a biosimilar bevacizumab. The company has operations in North America, Asia, and Europe. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.
See More
Previous Close:
$7.94
Open:
$8.03
24h Volume:
3.30M
Relative Volume:
1.82
Market Cap:
$2.45B
Revenue:
$2.68B
Net Income/Loss:
$-184.45M
P/E Ratio:
-11.49
EPS:
-0.6805
Net Cash Flow:
$229.23M
1W Performance:
+0.90%
1M Performance:
+5.39%
6M Performance:
+0.51%
1Y Performance:
+15.85%
1-Day Range:
Value
$7.76
$8.03
1-Week Range:
Value
$7.75
$8.11
52-Week Range:
Value
$6.29
$9.475

Amneal Pharmaceuticals Inc Stock (AMRX) Company Profile

Name
Name
Amneal Pharmaceuticals Inc
Name
Phone
908-947-3120
Name
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater
Name
Employee
5,210
Name
Twitter
@amnealpharma
Name
Next Earnings Date
2025-05-02
Name
Latest SEC Filings
Name
AMRX's Discussions on Twitter

Compare AMRX with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - Specialty & Generic icon
AMRX
Amneal Pharmaceuticals Inc
7.82 2.45B 2.68B -184.45M 229.23M -0.6805
Drug Manufacturers - Specialty & Generic icon
RGC
Regencell Bioscience Holdings Ltd
38.01 303.95B 0 -5.87M -767.30K -0.45
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
157.17 74.39B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
10.41 48.97B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.77 47.39B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.95 20.17B 16.54B -1.64B 749.00M -1.45

Amneal Pharmaceuticals Inc Stock (AMRX) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-06-25 Initiated Goldman Buy
Feb-24-25 Upgrade JP Morgan Neutral → Overweight
Sep-06-24 Upgrade JP Morgan Underweight → Neutral
Apr-07-21 Resumed RBC Capital Mkts Sector Perform
Mar-08-21 Upgrade Goldman Sell → Buy
Dec-14-20 Upgrade Barclays Equal Weight → Overweight
Dec-14-20 Upgrade Guggenheim Neutral → Buy
Jul-27-20 Initiated Goldman Sell
May-12-20 Upgrade Guggenheim Sell → Neutral
Dec-12-19 Downgrade Raymond James Outperform → Mkt Perform
Nov-12-19 Downgrade JP Morgan Neutral → Underweight
Nov-07-19 Downgrade SVB Leerink Outperform → Mkt Perform
Jul-22-19 Upgrade SVB Leerink Mkt Perform → Outperform
Jul-11-19 Downgrade RBC Capital Mkts Outperform → Sector Perform
Jul-08-19 Upgrade Piper Jaffray Neutral → Overweight
Jun-11-19 Initiated Barclays Equal Weight
May-21-19 Upgrade Raymond James Mkt Perform → Strong Buy
Mar-20-19 Initiated SunTrust Buy
Mar-08-19 Downgrade SVB Leerink Outperform → Mkt Perform
Dec-14-18 Downgrade Morgan Stanley Overweight → Equal-Weight
Oct-16-18 Downgrade SunTrust Buy → Hold
Aug-13-18 Upgrade RBC Capital Mkts Sector Perform → Outperform
Jul-23-18 Initiated Morgan Stanley Overweight
Jun-22-18 Initiated B. Riley FBR, Inc. Buy
View All

Amneal Pharmaceuticals Inc Stock (AMRX) Latest News

pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmac - GuruFocus

Jun 18, 2025
pulisher
Jun 18, 2025

Insider Sell: Gautam Patel Sells 94,906 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Parkinson’s Disease Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | AbbVie, Mitsubishi Tanabe Pharma (NeuroDerm), Cerevance, Amneal Pharma, Pharma Two B, Jazz Pharma - Barchart.com

Jun 17, 2025
pulisher
Jun 17, 2025

Parkinson's Disease Market to Show Remarkable Growth Trends - openPR.com

Jun 17, 2025
pulisher
Jun 13, 2025

Are Medical Stocks Lagging Amneal Pharmaceuticals (AMRX) This Year? - Yahoo Finance

Jun 13, 2025
pulisher
Jun 13, 2025

Epinephrine Autoinjector Market Size, Share, and Competitive - openPR.com

Jun 13, 2025
pulisher
Jun 13, 2025

FDA approves Amneal’s prednisolone acetate eye drops, launch set for Q3 - Investing.com India

Jun 13, 2025
pulisher
Jun 12, 2025

Insider Sell: Gautam Patel Sells 56,426 Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals receives U.S. FDA approval for prednisolone acetate - TipRanks

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic Suspension - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Amneal Pharmaceuticals (AMRX) Gains FDA Approval for Eye Drug | AMRX Stock News - GuruFocus

Jun 12, 2025
pulisher
Jun 12, 2025

FDA Green Lights Amneal's $201M Generic Eye Drug: Q3 2025 Launch Set for Pred Forte Alternative - Stock Titan

Jun 12, 2025
pulisher
Jun 11, 2025

Amneal Recalls Oral Antibiotic Over Contamination Issue - Infectious Disease Advisor

Jun 11, 2025
pulisher
Jun 10, 2025

Teva, Amneal rated Buy, Viatris Neutral as Goldman Sachs reviews generics space - MSN

Jun 10, 2025
pulisher
Jun 10, 2025

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision By Investing.com - Investing.com Canada

Jun 10, 2025
pulisher
Jun 10, 2025

Amneal Pharmaceuticals at Goldman Sachs Conference: Strategic Growth Vision - Investing.com

Jun 10, 2025
pulisher
Jun 09, 2025

Selective Estrogen Receptor Modulators Market Research 2025-2030: Leading Players Shaping the Future of Selective Estrogen Receptor Modulators Industry - GlobeNewswire Inc.

Jun 09, 2025
pulisher
Jun 09, 2025

Analysts Set Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) PT at $11.60 - Defense World

Jun 09, 2025
pulisher
Jun 08, 2025

Wellington Management Group LLP Has $586,000 Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 08, 2025
pulisher
Jun 07, 2025

Amneal Pharmaceuticals (NASDAQ:AMRX) Coverage Initiated by Analysts at The Goldman Sachs Group - Defense World

Jun 07, 2025
pulisher
Jun 07, 2025

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $2.52 Million Stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 07, 2025
pulisher
Jun 06, 2025

Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris? - Benzinga

Jun 06, 2025
pulisher
Jun 06, 2025

Teva stock, Amneal stock, rated Buy at Goldman (TEVA:NYSE) - Seeking Alpha

Jun 06, 2025
pulisher
Jun 06, 2025

Amneal recalls oral antibiotic due to bacterial contamination - MSN

Jun 06, 2025
pulisher
Jun 06, 2025

AMRX Stock Coverage Initiated with Buy Rating by Goldman Sachs | AMRX Stock News - GuruFocus

Jun 06, 2025
pulisher
Jun 06, 2025

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating - Investing.com

Jun 06, 2025
pulisher
Jun 06, 2025

Goldman Sachs initiates Amneal Pharmaceuticals stock with neutral rating By Investing.com - Investing.com UK

Jun 06, 2025
pulisher
Jun 06, 2025

Two Sigma Advisers LP Sells 32,400 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Amneal Pharmaceuticals at Jefferies Conference: Strategic Growth Insights By Investing.com - Investing.com Canada

Jun 05, 2025
pulisher
Jun 05, 2025

Amneal Pharmaceuticals Initiates Nationwide Recall of Contaminated Sulfamethoxazole/Trimethoprim Tablets - Insider Monkey

Jun 05, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Antibiotic Due to Contamination - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal announces recall of oral antibiotic (AMRX:NASDAQ) - Seeking Alpha

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Pharmaceuticals (AMRX) Recalls Contaminated Tablets Due t - GuruFocus

Jun 04, 2025
pulisher
Jun 04, 2025

Amneal Recalls Three Lots of Urinary Tract Infection Tablets - marketscreener.com

Jun 04, 2025
pulisher
Jun 04, 2025

Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to Trade - sharewise

Jun 04, 2025
pulisher
Jun 01, 2025

Amneal Pharmaceutical LLC Issues a Nationwide Recall of Sulfamethoxazole / Trimethoprim Tablets, USP, 400 mg/80 mg Only, Due to Microbial Contamination - US Recall News

Jun 01, 2025
pulisher
May 29, 2025

Amneal to Participate at Upcoming Investor Conferences in June - GlobeNewswire

May 29, 2025
pulisher
May 29, 2025

Amneal CEO and CFO Set for Exclusive Presentations at Two Major Healthcare Investor Conferences - Stock Titan

May 29, 2025
pulisher
May 29, 2025

Bank of America Corp DE Has $4.41 Million Position in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 29, 2025
pulisher
May 28, 2025

FDA approves Amneal’s DHE migraine/cluster headache autoinjector - MSN

May 28, 2025
pulisher
May 28, 2025

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Has $716,000 Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 28, 2025
pulisher
May 27, 2025

Pharyngitis Treatment Market with Antibiotics and Home - openPR.com

May 27, 2025
pulisher
May 26, 2025

3 Reasons Growth Investors Will Love Amneal (AMRX) - Yahoo Finance

May 26, 2025
pulisher
May 26, 2025

Deutsche Bank AG Has $1.06 Million Stock Holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) - Defense World

May 26, 2025
pulisher
May 22, 2025

Hydroxychloroquine Market to Witness Remarkable Growth with - openPR.com

May 22, 2025
pulisher
May 22, 2025

Insider Sell: Nikita Shah Sells Shares of Amneal Pharmaceuticals Inc (AMRX) - GuruFocus

May 22, 2025
pulisher
May 21, 2025

Migraine Market Enters New Era Following Satsuma Pharmaceuticals' ATZUMI and Amneal Pharmaceuticals' BREKIYA Regulatory Approval | DelveInsight - PR Newswire

May 21, 2025
pulisher
May 20, 2025

Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by BNP Paribas Financial Markets - Defense World

May 20, 2025

Amneal Pharmaceuticals Inc Stock (AMRX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Amneal Pharmaceuticals Inc Stock (AMRX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Shah Nikita
Executive Vice President
May 16 '25
Sale
7.58
49,140
372,481
388,929
$13.46
price up icon 0.98%
$8.87
price up icon 1.14%
$126.55
price down icon 0.60%
$290.75
price down icon 0.33%
drug_manufacturers_specialty_generic RDY
$15.23
price up icon 0.26%
$16.95
price down icon 0.64%
Cap:     |  Volume (24h):